Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	3.09T
Revenue (ttm)	1.50T
Net Income (ttm)	143.50B
Shares Out	12.68M
EPS (ttm)	11,316.84
PE Ratio	21.56
Forward PE	19.26
Dividend	500.00 (0.20%)
Ex-Dividend Date	Dec 27, 2024

Volume	62,486
Average Volume	118,257
Open	244,000
Previous Close	249,500
Day's Range	241,500 - 246,000
52-Week Range	233,000 - 375,000
Beta	0.50
RSI	41.72
Earnings Date	Apr 30, 2025

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,330
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 143.50 billion, a decrease of -1.87%.